{
    "clinical_study": {
        "@rank": "149851", 
        "arm_group": [
            {
                "arm_group_label": "Concurrent chemoradiation + adjuvant chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy"
            }, 
            {
                "arm_group_label": "Concurrent chemoradiation", 
                "arm_group_type": "Active Comparator", 
                "description": "IMRT combine with cisplatin concurrent chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an  randomized, controlled, multicenter phase II clinical trial. The purpose of this\n      study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with\n      or without capecitabine as adjuvant chemotherapy in local advanced high risk nasopharyngeal\n      carcinoma."
        }, 
        "brief_title": "Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Local Advanced High Risk Nasopharyngeal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)\n\n          -  Clinical stage III~IVb(UICC 7th)\n\n          -  Meet at least one factor below :1 primary tumor SUVmax>10 in 18F-FDG PET/CT;2 primary\n             tumor volume\uff1e30cm3;3 mutiple metastatic cervical lymph node with at least one's short\n             diameter\uff1e4cm; 4 T4N2M0; 5 T1-4N3M0;6 EBV-DNA\uff1e2\u00d710E4 copy/l\n\n          -  Range from 18\uff5e70 years old\n\n          -  WBC count \u2265 4\u00d7109/L\uff0cHemoglobin \u2265 100g/L\uff0c platelet count \u2265 100\u00d7109/L\n\n          -  ALT or AST \uff1c 2.5\u00d7ULN\u3001bilirubin \uff1c 1.5\u00d7ULN\n\n          -  OSerum creatinine \uff1c 1.5\u00d7ULN\n\n        Exclusion Criteria:\n\n          -  Central nervous system metastases\n\n          -  Suitable for local treatment\n\n          -  Uncontrolled seizure disorder or other serious neurologic disease\n\n          -  Clinically significant cardiac or respiratory disease\n\n          -  Drug or alcohol addition\n\n          -  Do not have full capacity for civil acts\n\n          -  Severe complication, active infection\n\n          -  Concurrent immunotherapy or hormone therapy for other diseases\n\n          -  Pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "258", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143388", 
            "org_study_id": "CCRT-AC-LAHR-NPC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Concurrent chemoradiation", 
                "description": "Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.", 
                "intervention_name": "IMRT combine with cisplatin concurrent chemotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Concurrent chemoradiation + adjuvant chemotherapy", 
                "description": "Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.", 
                "intervention_name": "IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Cisplatin", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Local advanced", 
            "high risk", 
            "nasopharyngeal carcinoma"
        ], 
        "lastchanged_date": "May 18, 2014", 
        "link": {
            "description": "Home Page of Cancer Center, Sun Yat-sen University", 
            "url": "http://www.sysucc.org.cn"
        }, 
        "location": {
            "contact": {
                "email": "zhaochong@sysucc.org.cn", 
                "last_name": "Zhao chong, M.D", 
                "phone": "+86-13902206160"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong"
                }, 
                "name": "Cancer Center, Sun Yat-sen University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial", 
        "other_outcome": [
            {
                "measure": "Three-year locoregional relapse free survival rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Three-year distance metastasis free survival rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Three-year overall survival rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "To evaluate the late toxicity with the RTOG/EORTC criterion when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.", 
                "measure": "Late Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "overall_contact": {
            "email": "shenguanzhu@gmail.com", 
            "last_name": "shen guanzhu, M.D", 
            "phone": "+86-13427529949"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "zhao chong, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Defined as the time in months from first dose of cisplatin until PD is observed or death occurs due to any cause.", 
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143388"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Zhao Chong", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the acute toxicity with CTC 3.0 when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.", 
            "measure": "Acute Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "First People's Hospital of Foshan", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangzhou General Hospital of Guangzhou Military Command", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Zhao Chong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}